U.S. FDA has informed the company that following additional consideration the
available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of
the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients
with steroid-refractory acute graft versus host disease (SR-aGVHD).
“We thank the agency for their collaborative approach. The responses and guidance from FDA are clear
and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SRaGVHD,” said Mesoblast CEO Dr. Silviu Itescu.
Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining
product characterization issues.
Directors walking the talk
Reg- looking forward to a hot august night
- Forums
- ASX - By Stock
- Ann: Appendix 3Y for Eric Rose
U.S. FDA has informed the company that following additional...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.8¢ |
Change
0.018(1.80%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
96.5¢ | 99.5¢ | 96.5¢ | $955.5K | 976.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 19355 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 113572 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 13041 | 0.985 |
12 | 94804 | 0.980 |
6 | 48379 | 0.975 |
11 | 122731 | 0.970 |
5 | 99741 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 99271 | 20 |
0.995 | 272682 | 22 |
1.000 | 238243 | 20 |
1.015 | 15000 | 1 |
1.020 | 16909 | 4 |
Last trade - 11.24am 26/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online